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INTRODUCTION
Bone tissue engineering or regenerative medicine uses cells or stem cells stimulated with e.g. growth factors, and seeded on (biodegradable) scaffolds to replace tissues and organs. 1 The stem cells used for bone tissue engineering should preferably be autologous and adult, to circumvent unwanted immune responses or ethical controversy. 2, 3 Adipose tissue has been described as a source of autologous and adult mesenchymal stem cells, and forms an alternative to bone marrow due to its easy accessibility by liposuction. 4, 5 Adipose tissue-derived mesenchymal stem cells (AT-MSCs) can differentiate along the osteogenic, adipogenic, chondrogenic, myogenic, and even neuronal pathways. 2, 4, 5 AT-MSCs show bone cell-like responsiveness to fluid shear stress after treatment with 1,25 dihydroxyvitamin D 3 , which stimulates osteogenic differentiation, by increasing their nitric oxide production and cyclooxygenase 2 gene expression. 6 In addition, AT-MSCs show increased runtrelated factor-2 (runx-2) and osteopontin gene expression in response to only 15 min of treatment with bone morphogenetic protein 2 (BMP-2). 7 
BMP-2 is a Food and Drug
Administration approved growth factor, which is already in clinical use, e.g. to promote spinal fusion. 8, 9 For bone tissue engineering AT-MSCs can be isolated from adipose tissue, followed by a short stimulation with a growth factor such as BMP-2 to induce osteogenic differentiation. The stimulated AT-MSCs can then be seeded on a scaffold and immediately implanted into the patient's spine, all within one spinal interbody fusion surgical procedure. 3, 7 Bone tissue engineering requires cells that are able to generate bone extracellular matrix in order to provide the mechanical properties allowing proper bone functioning. The principal components of bone extracellular matrix are anorganic hydroxyapatite and organic collagen, mainly type I collagen. 10 Fibrillar type I collagen is the major type of collagen present in bone extracellular matrix, and responsible for the elasticity of bone tissue. 10 Type I collagen is synthesized by the bone forming osteoblasts, and is composed of a triple helix of two α1(I)procollagen chains (COL1A1) and one α2(I)procollagen chain (COL1A2). 11 The procollagen chains are post-translationally modified in order to promote the fibrillar supramolecular structure of collagen, that is responsible for the mechanical resilience of the tissue. 11 Hydroxylation of the proline and lysine residues is catalyzed by prolyl hydroxylases and lysyl hydroxylases, respectively. 11 Hydroxyproline is essential for intramolecular hydrogen bonds within the triple helical domains. 11 Specific hydroxylysine residues serve as attachment sides for galactose or glucosylgalactose and are involved in the intermolecular cross-linking process, providing collagen with its tensile strength. 12 Stable cross-links can be formed in between separate collagen triple helices in the extracellular matrix after lysyl oxidase (LOX) has catalyzed the formation of aldehydes of the lysine or hydroxylysine residues in the telopeptides.
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These cross-links are a prerequisite for the physical and mechanical properties of collagen fibrils and for the formation of a stable collagen network (reviewed by Gelse et al.
).
The lysyl hydroxylase family of enzymes consists of lysyl hydroxylase 1, 2, and 3. [13] [14] [15] [16] Lysyl hydroxylases 1 and 3 hydroxylate lysine residues within the triple helical region of the collagen molecule. 17 In addition, lysyl hydroxylase 3 has been shown to exhibit collagen glucosyltransferase and galactosyltransferase activity. 15, 18, 19 Lysyl hydroxylase 2 is held responsible for hydroxylation of telopeptidal lysine residues situated at the terminal ends of the collagen triple helix. 20 Lysyl hydroxylases 1, 2, and 3 are encoded by procollagen-lysine, 2-oxoglutatarate 5-dioxygenase 1 (PLOD1), PLOD2, and PLOD3, respectively. [13] [14] [15] [16] 21 Mutations in these genes are responsible for defective collagen assembly and result in human pathologies; mutations in PLOD1 or PLOD2 result in Ehlers-Danlos syndrome type VI or Bruck syndrome. 20, [22] [23] [24] Members of the transforming growth factor beta (TGF-β) superfamily are currently under investigation for bone tissue engineering applications. 7, [25] [26] [27] These growth factors play a key role in skeletogenesis, i.e. during endochondral and intramembranous bone formation. 28, 29 Especially bone morphogenetic protein-2 (BMP-2) and TGF-β1 are under evaluation for use in bone tissue engineering. 7, 26 Both BMP-2 and TGF-β1 are present in the bone extracellular matrix, where TGF-β1
is the most abundant. Unlike BMP-2, TGF-β1 will not produce bone when injected into ectopic sites. [30] [31] [32] Both growth factors induce differentiation of stem cells along the osteogenic lineage, and stimulate type I collagen production by the cells. 7, 25, 33 Post-translational modification of collagen is a prerequisite for the development of functional bone tissue, as desired in bone tissue engineering, but it
has not yet been studied in AT-MSCs in response to BMP-2 or TGF-β1 treatment.
We hypothesize that AT-MSCs are able to post-translationally modify type I collagen and thereby promote formation of an appropriate functional extracellular matrix. To address this issue we have assessed gene expression of COL1A2, and collagenmodifying enzymes LOX and lysyl hydroxylases 1, 2, and 3 (PLOD1, PLOD2, and PLOD3) by AT-MSCs. Alkaline phosphatase activity was used as an indication of osteogenic differentiation of AT-MSCs.
MATERIALS AND METHODS

Donors
Human subcutaneous adipose tissue samples were obtained as waste material after elective surgery and donated upon informed consent of the patients by surgery departments of clinics in The Netherlands. Adipose tissue was taken from three female patients (age: 16, 36, and 37 years). The ethical review board of the Vrije Universiteit approved the protocol.
AT-MSC isolation and storage
Human adipose tissue was harvested by tumescent liposuction or resection. ATMSCs were isolated from the lipoaspirate or the resection material as described earlier with minor modifications. [4] [5] [6] [7] 34 Briefly, the harvested tissue was enzymatically 
AT-MSC culture
Cryopreserved, AT-MSCs containing cell suspensions were thawed and seeded at 4-10 x 10 4 cells/cm 2 in culture medium which was composed of D-MEM containing 10%
FBS (Gibco, Paisley, UK) supplemented with 500 µg/ml streptomycin sulphate (Sigma-Aldrich, St. Louis, MO, USA), 600 µg/ml penicillin (Sigma-Aldrich), and 2.5 µg/ml amphotericin B (Fungizone, Gibco). AT-MSCs were incubated at 37°C under 5% CO 2 in a humidified atmosphere, and medium was exchanged every three to four days. The culture period right after isolation is defined as passage 0. Upon confluence, AT-MSCs were harvested using 0.25% trypsin and 0.1% EDTA in PBS, seeded in 75 cm 2 culture flasks (Greiner Bio-One, Kremsmuenster, Austria), and cultured until the cell layer reached confluence again (passage 1). AT-MSCs used in this study where used at passage two or passage three.
AT-MSC characterization
Human AT-MSCs at passage 1 were analyzed for the expression of the mesenchymal stem cells surface markers CD105/endoglin and CD166/ALCAM by fluorescence-activated cell sorting (FACS) as described earlier. CD105/endoglin and 59% was positive for the mesenchymal stem cell marker CD166/ALCAM. 35 More than 60% of the AT-MSC population showed the marker profile, CD31 -CD34 + CD45 -CD90 + CD105 + CD166 + as described earlier.
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BMP-2 and TGF-β1
Recombinant human BMP-2 (Peprotech EC LTD, London, UK) was reconstituted at 100 µg/ml in PBS containing 0.1% BSA. Recombinant human TGF-β1 (SigmaAldrich) was reconstituted at 2 µg/ml in 4 mM HCl containing 0.1% BSA (SigmaAldrich). AT-MSCs were treated with either BMP-2 at 10 and 100 ng/ml or 1 and 10 ng/ml TGF-β1 for 4, 7, and 28 days. AT-MSCs, which were harvested after 4 and 7 days of treatment with BMP-2 or TGF-β1, were seeded at 10 4 cells/cm 2 , and ATMSCs harvested after 28 days of growth factor treatment at 5 x 10 3 cells/cm 2 . Cells were cultured in D-MEM with 10% FBS, antibiotics, funghizone, 10 mM β-glycerophosphate, 50 µg/ml ascorbic acid, and either 10 or 100 ng/ml BMP-2, or 1 or 10 ng/ml TGF-β1 for 4, 7, and 28 days. Control cultures were cultured without BMP-2 or TGF-β1.
Alkaline phosphatase
Alkaline phosphatase (ALP) activity was measured in order to assess the osteoblastic phenotype of AT-MSCs after 4, 7, and 28 days of treatment with BMP-2 and TGF-β1. ALP activity and protein content were determined in the cell layer. ALP activity was measured in the cell lysate using p-nitrophenyl phosphate (Merck, Darmstadt, Germany) as a substrate at pH 10.3, according to the method described by Lowry. 37 The absorbance was read at 410 nm with a microplate reader (BioRad Laboratories Inc., Hercules, CA, USA). The amount of protein in the AT-MSC layer was measured using a BCA protein assay reagent kit (Pierce, Rockford, IL, USA), and the absorbance was read at 570 nm with a microplate reader. ALP activity values were expressed per amount of protein in the AT-MSC layer.
Gene expression
Total RNA was isolated from AT-MSCs after 4, 7, and 28 days of treatment with or without BMP-2 or TGF-β1 using Trizol ® (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. cDNA synthesis was performed using 0. COL1A2, α2(I)procollagen; PLOD1,2, and 3, procollagen-lysine, 2-oxoglutatarate 5-dioxygenase 1, 2, and 3 Differences within groups were tested with a one-tailed paired t-test. Gene expression data are expressed as mean ± SEM of growth factor treated-over-control ratios (T/C) of target gene expression (PLOD1, 2, 3, and LOX) normalized for 18S or COL1A2 gene expression. Differences of T/C ratios were tested with a one-tailed ttest for single group mean and compared to 1 (T/C=1, no effect). Differences were considered significant if p<0.05.
RESULTS
The protein content of AT-MSC cultures increased during the 28 day-culture period.
Neither BMP-2 nor TGF-β1 affected the total amount of protein compared to untreated controls at all time points (control, 130 ± 66 (day 4); 196 ± 49 (day 7); 645 ± 124 (day 28); BMP-2, 131 ± 28 (day 4); 223 ± 27 (day 7); 574 ± 64 (day 28); TGF-β1, 135 ± 22 (day 4); 243 ± 26 (day 7); 680 ± 62 (day 28); values are mean ± SEM in µg/well).
BMP-2 (100 ng/ml) increased ALP activity, which indicates osteogenic differentiation of AT-MSCs, by 1.2-fold at day 28, whereas TGF-β1 had no effect ( Fig   1A) . BMP-2 (10 and 100 ng/ml), and TGF-β1 (10 ng/ml) up-regulated gene expression of COL1A2, the substrate for collagen modifying enzymes, by 1.2 to 1.8-fold at day 4 ( Fig 1B) .
Figure 1:
Effect of BMP-2 (10 and 100 ng/ml) or TGF-β1 (1 and 10 ng/ml) on alkaline phosphatase activity and α2(I)procollagen gene expression of AT-MSCs. (A) BMP-2 at 100 mg/ml increased alkaline phosphatase activity in AT-MSCs by 1.2-fold at day 28, but TGF-β1 had no effect. (B) BMP-2 at 100 ng/ml and TGF-β1 at 10 ng/ml upregulated COL1A2 gene expression by 1.2 and 1.8-fold, respectively at day 4. Values are mean ± SEM. BMP-2, bone morphogenetic protein-2; TGF-β1, transforming growth factor-β1; ALP, alkaline phosphatase; COL1A2, α2(I)procollagen. Significant effect of growth factor, *p<0.05.
In order to study the relation between collagen-modifying enzymes PLOD1, 2, 3 and LOX and their substrate COL1A2 in the cell, the ratio of each gene to the substrate was calculated. PLOD2 encodes lysyl hydroxylase 2, the lysyl hydroxylase responsible for hydroxylation of the telopeptidal lysine residues. BMP-2 at 10 and 100 ng/ml or TGF-β1 at 1 and 10 ng/ml did not affect PLOD2 gene expression by ATMSCs at day 4, 7, and 28 (Fig 2A) . PLOD2 gene expression relative to COL1A2 was decreased after treatment with BMP-2 (10 and 100 ng/ml) by 1.3 to 1.5-fold at day 4, and by 1.6-fold after treatment with TGF-β1 (10 ng/ml) for 28 days (Fig 2B) . BMP-2 (10 ng/ml) increased PLOD2 gene expression relative to COL1A2 by 1.7 and 1.8-fold at day 7 and 28, and BMP-2 (100 ng/ml) by 1.6-fold at day 28 ( Fig 2B) . BMP-2 at 10 and 100 ng/ml down-regulated PLOD2 gene expression by 1.5 and 1.3-fold, respectively at day 4, but TGF-β1 had no effect. BMP-2 at 10 ng/ml increased PLOD2 gene expression relative to COL1A2 by 1.7-fold in AT-MSCs at day 7, but TGF-β1 had no effect. BMP-2 at 10 and 100 ng/ml increased PLOD2 gene expression relative to COL1A2 in ATMSCs by 1.8 and 1.6-fold, respectively, whereas TGF-β1 decreased PLOD2 gene expression relative to COL1A2 by 1.6-fold at day 28. Values are mean ± SEM. Realtime PCR data were normalized for 18S gene expression. BMP-2, bone morphogenetic protein-2; TGF-β1, transforming growth factor-β1; PLOD2, procollagen-lysine, 2-oxoglutatarate 5-dioxygenase 2; COL1A2, α2(I)procollagen. Significant effect of growth factor, * p<0.05, ** p<0.01. (A) Both BMP-2 at 100 ng/ml and TGF-β1 at 10 ng/ml up-regulated PLOD1 gene expression by 1.5-fold at day 4. BMP-2 at 10 ng/ml and TGF-β1 at 1 ng/ml down-regulated PLOD1 gene expression by 1.7 and 2.1-fold at day 28. (B) TGF-β1 at 10 ng/ml at day 7 and TGF-β1 at 1 and 10 ng/ml at day 28 decreased PLOD1 gene expression relative to COL1A2 by 1.3 to 2-fold. BMP-2 had no effect. (C) TGF-β1 at 10 ng/ml down-regulated PLOD3 gene expression by 1.9-fold at day 28, but BMP-2 did not. (D) TGF-β1 at 10 ng/ml down-regulated PLOD3 gene expression relative to COL1A2 by 2.3-fold at day 28, but BMP-2 had no effect.
Values are mean ± SEM. Real-time PCR data were normalized for 18S gene expression. BMP-2, bone morphogenetic protein-2; TGF-β1, transforming growth factor-β1; PLOD1 and 3, procollagen-lysine, 2-oxoglutatarate 5-dioxygenase 1 and 3; COL1A2, α2(I)procollagen. Significant effect of growth factor, * p<0.05, ** p<0.01, *** p<0.001.
Figure 4:
Effect of BMP-2 (10 and 100 ng/ml) or TGF-β1 (1 and 10 ng/ml) on gene expression of lysyl oxidase in AT-MSCs. (A) BMP-2 at 10 and 100 ng/ml upregulated LOX gene expression by 1.7 to 1.8-fold at day 7. TGF-β1 at 10 ng/ml upregulated LOX gene expression by 1.9-fold at day 4. (B) BMP-2 and TGF-β1 did not affect LOX gene expression relative to COL1A2. Values are mean ± SEM. Real-time PCR data were normalized for 18S gene expression. BMP-2, bone morphogenetic protein-2; TGF-β1, transforming growth factor-β1; LOX, lysyl oxidase; COL1A2, α2(I)procollagen. Significant effect of growth factor, * p<0.05, ** p<0.01.
PLOD1 and PLOD3 encode the lysyl hydroxylases hydroxylating triple helical lysine residues, lysyl hydroxylase 1 and 3. Both BMP-2 (100 ng/ml) and TGF-β1 (10 ng/ml) up-regulated PLOD1 gene expression by 1.5-fold at day 4 ( Fig 3A) . However, BMP-2 (10 ng/ml) and TGF-β1 (1 ng/ml) down-regulated PLOD1 gene expression by 1.7 to 2.1-fold at day 28 ( Fig 3A) . BMP-2 (100 ng/ml) increased PLOD1 gene expression relative to COL1A2 by 1.4-fold at day 4. TGF-β1 (1 and 10 ng/ml) decreased PLOD1 gene expression relative to COL1A2 by 1.3 to 2-fold at day 4, 7
and 28 ( Fig 3B) . TGF-β1 (10 ng/ml) decreased PLOD3 gene expression by 1.9-fold at day 28, but BMP-2 had no effect (Fig 3C) . PLOD3 gene expression relative to COL1A2 was decreased by 2.3-fold after treatment with TGF-β1 (10 ng/ml) at day 28, whereas BMP-2 had no effect (Fig 3D) .
The enzyme LOX catalyzes the oxidative deamination of telopeptidyl lysyl and hydroxylysyl residues of collagen in the extracellular space. BMP-2 (10 and 100 ng/ml) up-regulated LOX gene expression by 1.7 to 1.8 fold at day 7 ( Fig 4A) . TGF-β1 (10 ng/ml) up-regulated LOX gene expression by 1.9-fold at day 4 ( Fig 4A) . BMP-2 and TGF-β1 did not affect LOX gene expression relative to COL1A2 (Fig 4B) .
DISCUSSION
For appropriate functioning of engineered tissue, an extracellular matrix, that is either provided in form of scaffolds or produced by the cells themselves, is of utmost importance. 38 Organic bone extracellular matrix, which is mainly composed of covalently cross-linked type I collagen, is a prerequisite for proper bone function. 39 BMP-2 and TGF-β1 are important growth factors present in bone extracellular matrix, and are involved in bone formation and bone morphogenesis. 28, 29 Unlike BMP-2, TGF-β1 will not produce bone when injected into ectopic sites. [30] [31] [32] The present study increased, but TGF-β1 decreased PLOD1-over COL1A2-ratio. PLOD3-over COL1A2
was decreased by TGF-β1, whereas BMP-2 had no effect. BMP-2 and TGF-β1 differentially affected the expression of PLOD1, 2, 3, and LOX relative to COL1A2.
This suggests that the type I collagen matrix, that is synthesized by AT-MSCs, might be post-translationally modified and that this modification is differentially affected dependent on the growth factor added.
PLOD2 gene expression increases in murine bone marrow-derived mesenchymal stem cells at the onset of mineralization, and lysyl hydroxylase 2 has been suggested to be responsible for telopeptidal lysyl hydroxylation in bone. 40 However, substrate specificity of any of the known lysine hydroxylases, e.g. for type I collagen, can not be assigned. 41 Patients suffering from Bruck syndrome show skeletal defects such as short stature or osteoporosis, and underhydroxylation of type I collagen and aberrant cross-linking, which leads to the observed phenotype. 20, [22] [23] [24] A mutation in PLOD2 is responsible for this Bruck syndrome in a subset of patients and lysyl hydroxylase 2 has been identified as telopeptidal lysyl hydroxylase. 20, 22, 23 Lysyl hydroxylase 2b, a splice variant of lysyl hydroxylase 2, has been associated with collagen cross-linking in MC3T3-E1 osteoblasts, and lysysl hydroxylase 2b over-expression results in defective matrix mineralization by MC3T3-E1 cells. 42, 43 Therefore, the increase in PLOD2 relative to COL1A2 gene expression caused by BMP-2 treatment of AT-MSCs suggests that telopeptidal hydroxylysine may be present, and that the trivalent mature cross-links, hydroxylysyl pyridinoline and lysyl pyrodinoline, may be formed. Whether lysyl hydroxylase 2b is expressed in differentiating AT-MSCs, and whether lysyl hydroxylase 2b expression levels change during the course of osteogenic differentiation is subject of further study.
Lysyl hydroxylase 1 and lysyl hydroxylase 2 have been proposed to have telopeptidal lysine hydroxylation activity. 44, 45 BMP-2 induced PLOD1 gene expression, which is encoding lysyl hydroxylase 1. Lysyl hydroxylase 1 might be responsible for hydroxylation of triplehelical lysine-residues in type I collagen or other helical collagens, produced by differentiating AT-MSCs. This might compensate for a lack of, or for low telopeptidal hydroxylation activity of lysyl hydroxylase 2, since PLOD2 gene expression was not directly affected by BMP-2, but was increased relative to its substrate COL1A2. It is thus likely that telopeptidal hydroxylysyl residues are present and that AT-MSCs are able to form an appropriate extracellular matrix. This, however, does not explain the down-regulation of PLOD2 by BMP-2
andTGF-β1 at a late time point, which needs further investigation.
Lysyl hydroxylase 3, the product of the PLOD3 gene, is a multifunctional enzyme that does not only hydroxylate triple helical lysine residues, but also possesses collagen glucosyltransferase and galactosyltransferase activity. 15, 18, 19 Lysyl hydroxylase 3 has been proposed to affect matrix remodelling resulting from modification of proteins in the extracellular matrix, due to its localization in the extracellular space. 46 PLOD3 expression levels are not changed during MC3T3-E1 osteoblast differentiation, 46, 47 which might explain our finding that BMP-2 did not affect PLOD3 gene expression in AT-MSCs. Thus, PLOD3 might be constitutively expressed due to its extracellular matrix "housekeeping" function.
Glucosyltransferase and galactosyltransferase activity of lysyl hydroxylase 3 has been shown in, e.g. spleen, brain, and lung. 46 However, this has neither been studied LOX catalyses the oxidative deamination of telopeptidal lysyl or hydroxylysyl residue, forming aldehyde moieties, which is the final post-translational change of collagen before the formation of covalent cross-links. 39, 48 The enzyme is located in the extracellular space and interacts with the secreted collagen triple helices. 49, 50 LOX plays a key role in collagen deposition during the course of MC3T3-E1 osteoblast differentiation and chicken calvarial osteoblasts. 48, [51] [52] [53] In the current study, cells coincides with type I collagen gene expression. 52 In addition, processing of the LOX pro-enzyme appears to occur at all stages of osteoblast differentiation in MC3T3-E1. 48 This suggests that in our study, the osteogenically differentiating ATMSCs might post-translationally modify LOX. Thus active LOX might be present, which in turn modifies type I collagen synthesized by AT-MSCs. This might lead to appropriately cross-linked collagen in the extracellular matrix produced by AT-MSCs after treatment with BMP-2 or TGF-β1.
In conclusion, our findings indicate that treatment with BMP-2 or TGF-β1 changes the gene expression levels of collagen-modifying enzymes PLOD1, 2, 3, and LOX in AT-MSCs, and that BMP-2 and TGF-β1 have differential effects on the expression of collagen-modifying enzymes. Therefore, AT-MSCs may be able to appropriately modify type I collagen to form an organic bone extracellular matrix for tissue engineering purposes depending on the growth factor added.
